BRD4 and thyroid cancer: ARV-825, a BRD4 PROTAC, exhibits significant antitumor activity in various models (neuroblastoma, thyroid cancer, and T-ALL) by degrading the BRD4 protein and suppressing MYC expression, thereby inhibiting tumor cell proliferation [106,107,108].